TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Denosumab and Teriparatide Study (DATA-HD and DATA-EX)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* women aged 45+~* postmenopausal~* osteoporotic with high risk of fracture~Exclusion Criteria:~* no significant previous use of bone health modifying treatments

- Gender: FEMALE
- Minimum Age: 45 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Standard dose teriparatide (Type: ACTIVE_COMPARATOR): teriparatide daily subcutaneous injection (months 0-9) plus denosumab subcutaneous injection every 6 months (months 3-15) followed by zoledronic acid at month 15
- High dose teriparatide (Type: ACTIVE_COMPARATOR): teriparatide alternate dose daily subcutaneous injection (months 0-9) plus denosumab subcutaneous injection every 6 months (months 3-15) followed by zoledronic acid at month 15

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Lanreotide Autogel and Pegvisomant Combination Therapy in Acromegalic Patients

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* The patient must have had documentation supporting the diagnosis of acromegaly, including elevated GH and/or IGF-1 levels~* The patient is treated with pegvisomant, because of IGF-1 level remaining above ULN when treated with somatostatin analogue, on a daily basis for at least 3 months and has normal (age and sex adjusted) IGF-1 level, or IGF-1 level above the upper limit of normal (ULN) after treatment with pegvisomant 30 mg per day, OR the patient is treated with lanreotide Autogel or octreotide LAR for at least 6 months including 3 months at the highest marketed dose and has a serum IGF-1 level above ULN, 28 days after the last injection~* At the end of the run-in period, The patient has a serum IGF-1 level above 1.2 x ULN, or a serum IGF-1 level between ULN and 1.2 x ULN and a serum GH nadir \> 1 µg/L (assessed by an OGTT), 28 days after the 3rd injection of lanreotide Autogel 120 mg OR the patient is diabetic and has a serum IGF-1 level above 1.2 ULN, 28 days after the 3rd injection of lanreotide Autogel 120 mg~Exclusion Criteria:~* The patient has undergone pituitary surgery or radiotherapy within 6 months prior to study entry, or it is anticipated that it will be done during the study~* The patient has already been treated with a somatostatin analogue associated with a GH antagonist~* The patient has received dopamine agonist within 6 weeks prior to the study entry~* The patient has abnormal hepatic function at study entry (defined as AST, ALT, GGT, alkaline phosphatase, prothrombin time or total bilirubin above 2 ULN)~* The patient is at risk of pregnancy or is lactating

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Swallowing Impairment After COVID-19 Infection

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* People who tested positive or received a presumed positive diagnosis of COVID-19 infection not earlier than March 1, 2020 and who are at least 2 weeks post positive diagnosis and the initiation of medical management of COVID-19 infection~* Adequate comprehension of English to understand the consent form and follow study instructions~Exclusion Criteria:~* Age under 18 years old~* Current pregnancy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- COVID-19 Ventilated (Type: None): Participants who were diagnosed with COVID-19 prior to October, 2021 who required hospitalization in an ICU with mechanical ventilation during their illness.
- COVID-19 Non-Ventilated (Type: None): Participants who were diagnosed with COVID-19 prior to October, 2021 who did not require mechanical ventilation during their illness.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Phase 2 Study To Evaluate The Safety Of Apixaban In Atrial Fibrillation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Age ≥ 20 years outpatient (regardless of sex)~* Patients diagnosed as non-valvular atrial fibrillation (NVAF)~* One or more following risks of stroke.~Exclusion Criteria:~* Recent cerebral infarction (includes TIA) within 4 weeks of week 0.~* Subjects who have or are suspected to have a serious/hereditary bleeding tendency, such as disseminated intravascular coagulation syndrome (DIC), congenital platelet dysfunction and von Willebrand disease (those suspected from the family history are included).~* Subjects who have or are suspected to have a serious/hereditary thrombogenic tendency (those suspected from the family history are included) or those who require continuation of the Warfarin therapy.

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Apixaban 5mg BID (Type: EXPERIMENTAL): None
- Apixaban 2.5mg BID (Type: EXPERIMENTAL): None
- Warfarin (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Immunogenicity of Vi-CRM197 Vaccine Against S. Typhi in Children, Older Infants and Infants

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion criteria:~* Subjects belonging to 3 age groups will be enrolled into the trial: children (24 to 59 months of age at enrollment), older infants (9 to 12 months of age at enrollment) and infants (6 weeks of age at enrolment).~* Written informed consent will be obtained by the parents/ guardians before enrollment into the trial.~* Infants who have been vaccinated with BCG and HBV at birth and OPV at any time since birth can be enrolled into the trial, while infants who have received DTwP+HBV+Hib due at 6 weeks of age as per local EPI schedule cannot be enrolled into the trial.

- Gender: ALL
- Minimum Age: 6 Weeks
- Maximum Age: 59 Months
- Healthy Volunteers: t

Study Arms:
- Vi-CRM, Older infants (Type: EXPERIMENTAL): Older Infants (9 to 12 months) receiving 2 doses of NVGH Vi-CRM197 vaccine
- PNC13, Older infants (Type: ACTIVE_COMPARATOR): Older infants (9 to 12 months) receiving 2 doses of Pneumococcal conjugate vaccine
- Vi-CRM, Infants (Type: EXPERIMENTAL): Infants (6 to 8 weeks) receiving 3 doses of NVGH Vi-CRM197 vaccine
- PNC13, Infants (Type: ACTIVE_COMPARATOR): Infants (6 to 8 weeks) receiving 3 doses of Pneumococcal conjugate vaccine
- Vi-CRM, Children (Type: EXPERIMENTAL): Children (24 to 59 months) receiving 2 doses of NVGH Vi-CRM197 vaccine
- Vi-PS, Children (Type: ACTIVE_COMPARATOR): Children (24 to 59 months) receiving 1 dose of licensed Vi Polysaccharide vaccine and 1 dose of Pneumococcal conjugate vaccine

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Treatments for Anxiety: Meditation and Escitalopram

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Men and women between 18 and 75 years old.~2. Have an anxiety disorder, including: social anxiety disorder (SAD), generalized anxiety disorder (GAD), panic disorder, or agoraphobia~3. Must understand study procedure and be willing to participate in all testing visits and treatment as assigned.~4. Participants must be able to give informed consent to the study procedures.~Exclusion Criteria:~1. Comorbid psychiatric disorder other than anxiety or depression, such as psychotic disorder, post-traumatic stress disorder, obsessive compulsive disorder, eating disorders, bipolar disorder; developmental or organic mental disorders; and current (past 6 months) substance use disorders.~2. A serious medical condition that may result in surgery or hospitalization.~3. A history of head trauma causing loss of consciousness, or ongoing cognitive impairment~4. Inability to understand study procedures or informed consent process, or significant personality dysfunction likely to interfere with study participation (assessed during the clinical interview).~5. Subjects who will be non-compliant with the study procedures. This may include planned travel out of town.~6. Pregnancy as assessed by urine test at screen. Avoidance of pregnancy is also necessary for inclusion in the study.~7. Subjects taking barbiturates, SSRIs, anti-depressants, or antipsychotics. Sleep medications (other than anti-depressants) and benzodiazepines will be allowed, if has been taken at stable dose 4 weeks prior to baseline and the patient plans to continue at the same dose through the trial. Trazadone (for sleep) above 100mg will be disallowed.~8. Concurrent psychotherapy initiated within 1 month of screen interview, or ongoing psychotherapy of any duration directed specifically toward the treatment of anxiety (such as cognitive behavioral therapy).~9. Individuals who have completed a course of MBSR or an equivalent meditation training in the last year, or have an ongoing daily meditation practice~10. Individuals reporting significant active suicidal ideation or suicidal behaviors within the past year.~11. Individuals with a medical condition (i.e., epilepsy) that may be exacerbated by study treatment, as determined by a study physician or nurse practitioner based on history, physical, and/or labs.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Mindfulness-Based Stress Reduction (MBSR) (Type: EXPERIMENTAL): None
- Escitalopram (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Triple Antibiotic Paste as an Intracanal Medication With an Anti-Inflammatory Drug on Post-operative Pain.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Subject's age between 18-50 years.~2. Both male and female subjects.~3. Medically free and healthy subjects.~4. Mandibular and maxillary single rooted teeth.~5. Asymptomatic non vital teeth.~Exclusion Criteria:~1. Teeth with acute dentoalveolar abscess.~2. Subjects having more than one tooth that require root canal treatment.~3. Subjects that have taken analgesic, anti-inflammatory or antibiotic drugs during the 10 days prior to the start of treatment.~4. Pregnant females.~5. Subjects with systemic diseases who have endocrine diseases, Infectious diseases or Psychological disturbance.~6. Teeth with periodontal disease or pulp calcification.~7. Subjects taking chronic pain medications.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: t

Study Arms:
- Control: Calcium Hydroxide (Type: NO_INTERVENTION): Non-setting Calcium Hydroxide
- Test: Triple Antibiotic Paste and Anti-Inflammatory Drug (Type: OTHER): Mixture of ciprofloxacin, metronidazole and minocycline.and diclofenac potassium 50 mg (Catafast)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate the Efficacy and Safety of Glecaprevir (GLE)/Pibrentasvir (PIB) in Treatment-Naive Adults in Brazil With Chronic Hepatitis C Virus (HCV) Genotype 1 - 6 Infection

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Participant had positive plasma hepatitis C virus (HCV) antibody and HCV ribonucleic acid (RNA) viral load greater than or equal to 1000 IU/mL at Screening Visit.~* Participant must have been documented as without cirrhosis with METAVIR equivalent fibrosis stage of F2 to F3 or with compensated cirrhosis (F4) based on results of a liver biopsy, or FibroScan, or FibroTest score.~* Participants who were known to be HCV/Human Immunodeficiency Virus (HIV) co-infected may have been enrolled if they had a positive test result for anti-HIV antibody at Screening and were: naïve to treatment with any antiretroviral therapy (ART), or on a stable, qualifying HIV ART regimen for at least 8 weeks prior to Baseline.~* Participants with compensated cirrhosis only: Absence of hepatocellular carcinoma (HCC) within 3 months prior to Screening or a negative ultrasound at Screening.~Exclusion Criteria:~* Current hepatitis B virus (HBV) infection on screening tests.~* Any current or past clinical evidence of Child-Pugh B or C classification (score of \> 6) or clinical history of liver decompensation including ascites on physical exam, including hepatic encephalopathy or variceal bleeding.~* Receipt of any investigational or commercially available anti-HCV agents.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm A: Glecaprevir (GLE)/Pibrentasvir (PIB) for 8 weeks (Type: EXPERIMENTAL): Arm A: Hepatitis C virus (HCV) genotype (GT) 1 to GT6 participants without cirrhosis (fibrosis stage F2 to F3) received glecaprevir (GLE)/pibrentasvir (PIB) 300 mg/120 mg once daily (QD) for 8 weeks.
- Arm B: GLE/PIB for 12 Weeks (Type: EXPERIMENTAL): Arm B: HCV GT1 to GT6 participants with compensated cirrhosis (F4) received GLE/PIB 300 mg/120 mg QD for 12 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Treating PCOS With Digital Intervention vs. Metformin

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Female aged 18- 45; Meet Rotterdam criteria; Insulin Resistance~Exclusion Criteria:~Women who are pregnant or have a pregnancy plan within six months; Congenital adrenocortical hyperplasia; Hyperprolactinemia; Hyperthyroidism or hypothyroidism; Abnormal liver function (≥ 3 times the upper limit of the normal range); Abnormal renal function (GFR\<60ml/min/1.73m2); Adrenal or ovarian tumors secreting androgens; Used contraceptives, metformin, pioglitazone, and antidepressant medication in the last 3 months.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: f

Study Arms:
- Digital Intervention (Type: EXPERIMENTAL): A mini program-based digital intervention.
- Metformin (Type: ACTIVE_COMPARATOR): Traditional metformin monotherapy.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Phase 3 Study Comparing 2 Doses of CP-690,550 vs. Placebo for Treatment of Rheumatoid Arthritis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* The patient has a diagnosis of RA based upon the American College of Rheumatology (ACR) 1987 Revised Criteria.~* The patient has active disease at both Screening and Baseline, as defined by both: ≥6 joints tender or painful on motion; and ≥6 joints swollen; and fulfills 1 of the following 2 criteria at Screening: 1.ESR (Westergren method) \>28 mm in the local laboratory. 2. CRP \>7 mg/L in the central laboratory~* Patient had an inadequate response to at least one DMARD (traditional or biologic) due to lack of efficacy or toxicity.~* No evidence of active or latent or inadequately treated infection with Mycobacterium tuberculosis.~* Patient has washed out of all DMARDs other that antimalarials~Exclusion Criteria:~* Blood dyscrasias including confirmed: 1. Hemoglobin \<9 g/dL or Hematocrit \<30%; 2. White blood cell count \<3.0 x 109/L; 3. Absolute neutrophil count \<1.2 x 109/L; 4. Platelet count \<100 x 109/L~* History of any other autoimmune rheumatic disease other than Sjogren's syndrome~* No malignancy or history of malignancy.~* History of infection requiring hospitalization, parenteral antimicrobial therapy, or as otherwise judged clinically significant by the investigator, within the 6 months prior to the first dose of study drug

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Active 5mg (Type: EXPERIMENTAL): None
- Active 10 mg (Type: EXPERIMENTAL): None
- Placebo Sequence 1 (Type: PLACEBO_COMPARATOR): None
- Placebo Sequence 2 (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Atorvastatin Effects On Arterial Stiffness In Hemodialysis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients on regular hemodialysis treatment for more than 3 months~Exclusion Criteria:~* Patients with diabetes mellitus.~* Patients with known severe valvular heart disease.~* Irregular heart rhythm.~* History of aortic surgery/prosthetic aorta.~* Acute liver disease.~* Patients receiving lipid lowering drugs.~* Pregnancy.~* History of myocardial infraction in the previous 6 months.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Atorvastatin (Type: EXPERIMENTAL): They will receive atorvastatin 10 mg, as one tablet /day for 24 weeks.
- placebo (Type: PLACEBO_COMPARATOR): They will receive a placebo in the form of multivitamin tablets similar to the experimental drug with the same regimen, as one tablet /day for 24 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Dexpramipexole Dose-Ranging Biomarker Study in Subjects With Eosinophilic Asthma

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female ≥18 and \<75 years of age at the time of consent~* Physician diagnosis of asthma for ≥12 months (relative to Baseline) based on Global Initiative for Asthma (GINA) 2018 Guidelines~* Asthma requiring treatment with, at a minimum, low dose inhaled corticosteroids in combination with a long-acting β2 agonist, on a stable dose for at least 1 month before Screening~* Bronchodilator reversibility, as evidenced by ≥12% and ≥200 mL improvement in FEV1 15 to 25 minutes following inhalation of albuterol at Screening~* Pre-bronchodilator FEV1 ≥40% and \<80% of predicted at Screening and Baseline~* AEC ≥0.30 x10\^9/L at the Screening visit~* ACQ-7 ≥1.5 at Screening~* Negative pregnancy test at Baseline~* Adherence ≥85% with twice-daily placebo taken during the Run-in Period~Exclusion Criteria:~* Treatment for an asthma exacerbation within 8 weeks prior to Baseline visit~* Treatment with systemic corticosteroids in the 8 weeks prior to Screening~* Treatment with monoclonal antibody therapy, within 5-half-lives prior to Baseline~* Treatment with selected drugs known to have a substantial risk of neutropenia~* Absolute neutrophil count \<2.0x10\^9/L at Screening, or any documented history of absolute neutrophil count \<2.0x10\^9/L.~* Renal dysfunction, defined as an estimated glomerular filtration rate (eGFR) \<60 mL/min/1.73m\^2 at Screening~* Clinically significant abnormal laboratory or ECG values~* Other medically significant illness~* Use of any smoke or inhaled nicotine delivery device within 1 year prior to Screening~* Pregnant women or women breastfeeding~* Currently taking pramipexole or other dopamine agonists

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 74 Years
- Healthy Volunteers: f

Study Arms:
- placebo BID (Type: PLACEBO_COMPARATOR): Following a 2-4 week placebo run-in, randomized subjects received 1 tablet placebo twice daily for 12 weeks.
- 37.5 mg BID dexpramipexole (Type: ACTIVE_COMPARATOR): Following a 2-4 week placebo run-in, randomized subjects received 1 tablet of 37.5 mg dexpramipexole twice daily for 12 weeks.
- 75 mg BID dexpramipexole (Type: ACTIVE_COMPARATOR): Following a 2-4 week placebo run-in, randomized subjects received 1 tablet of 75 mg dexpramipexole twice daily for 12 weeks.
- 150 mg BID dexpramipexole (Type: ACTIVE_COMPARATOR): Following a 2-4 week placebo run-in, randomized subjects received 1 tablet of 150 mg dexpramipexole twice daily for 12 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete